Search | Clinical Trials Finder

Conditions: Spinal Cord Injuries, Constipation, Fecal Incontinence, Neurogenic Bowel
Interventions: Combination of Neostigmine and Glycopyrrolate, I-Box by Dynatronics; Drug · Device
Lead sponsor: James J. Peters Veterans Affairs Medical Center; Federal
Eligibility: 18 Years to 89 Years
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Chronic Pain, Acute Pain, Post Operative Pain, Fibromyalgia, Primary, Fibromyalgia, Secondary, Fibromyalgia, Irritable Bowel Syndrome, Chronic Headache Disorder, Chronic Migraine, Chronic Pelvic Pain Syndrome, Temporomandibular Joint Disorders, Endometriosis-related Pain, Arthritis, Chronic Low-back Pain, Failed Back Surgery Syndrome, Post Herpetic Neuralgia, Neuropathic Pain, Painful Diabetic Neuropathy, Painful Bladder Syndrome, Trauma-related Wound, Trauma, Multiple, Chronic Pain Syndrome, Chronic Shoulder Pain
Interventions: SOMA pain manager smartphone application; Device
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Irritable Bowel Syndrome, Cyclical Vomiting Syndrome, Ulcerative Colitis, Vulvodynia, Crohn's Disease
Interventions: Not listed
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 55 Years
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Irritable Bowel Syndrome
Interventions: Eluxadoline, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 26
States / cities: Hot Springs, Arkansas • Little Rock, Arkansas • Corona, California + 19 more

Conditions: Constipation Predominant, Irritable Bowel Syndrome (IBS-C)
Interventions: Tegaserod; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Irritable Bowel Syndrome, Vaginal Health
Interventions: Vaginal Probiotic; Dietary Supplement
Lead sponsor: Rael; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Irritable Bowel Syndrome, Constipation
Interventions: Lubiprostone, Placebo, Smartpill wireless motility capsule; Drug · Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Irritable Bowel Syndrome
Interventions: 0.075 mg RVX-100, 0.125 mg RVX-100, 0.250 mg RVX-100, placebo; Drug
Lead sponsor: Revogenex, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Chevy Chase, Maryland

Conditions: Irritable Bowel Syndrome
Interventions: Psyllium (0.7 g/year of age per day), Psyllium (0.5 g/year of age per day), Placebo, fructans; Drug · Other
Lead sponsor: Dr Bruno Chumpitazi, M.D.; Other
Eligibility: 12 Years to 17 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Colon, Irritable
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Irritable Bowel Syndrome
Interventions: FODMAP; Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Irritable Bowel Syndrome (IBS-C)
Interventions: Transcutaneous Auricular Vagus Nerve Stimulation (ta-VNS), Sham Transcutaneous Auricular Vagus Nerve Stimulation; Device
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Cancer
Interventions: Experimental: Mentored Gardening Intervention; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 60 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Colorectal Cancer, Adenomas Colon, Colon Cancer, Rectal Cancer, Colon Neoplasm, Colon Lesion, Colon Disease, Colon Polyp, Polyps, Adenoma, Rectal Diseases, Rectal Polyp, Gastrointestinal Neoplasms, Intestinal Neoplasms, Colonic Diseases, Functional, Intestinal Disease
Interventions: Next-Gen CRC Screening Test; Diagnostic Test
Lead sponsor: New Day Diagnostics; Network
Eligibility: 45 Years and older
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Chula Vista, California • San Diego, California

Conditions: Irritable Bowel Syndrome
Interventions: Dextofisopam; Drug
Lead sponsor: Pharmos; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 79
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 67 more

Conditions: Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea
Interventions: Rifaximin, Glucose and lactulose hydrogen breath testing; Drug · Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 80 Years
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Irritable Bowel Syndrome
Interventions: Olorinab, Placebo; Drug
Lead sponsor: Arena Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Irritable Bowel Syndrome
Interventions: Mindfulness training, Psycho-educational support group for women with IBS; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Irritable Bowel Syndrome
Interventions: Eluxadoline, Placebo; Drug
Lead sponsor: Furiex Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 232
States / cities: Birmingham, Alabama • Decatur, Alabama • Huntsville, Alabama + 189 more

Conditions: Functional Constipation, Gastric Emptying, Whole Gut Transit, Small Bowel Transit, Colonic Transit, Rectal Compliance, Rectal Sensation
Interventions: Daikenchuto (TU-100), Placebo; Drug
Lead sponsor: Tsumura USA; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Irritable Bowel Syndrome
Interventions: Rifaximin; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 525 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 67
States / cities: Scottsdale, Arizona • Tempe, Arizona • Anaheim, California + 61 more

Conditions: Ulcerative Colitis, Crohn Disease, Obesity, Colon Polyp, Eosinophilic Esophagitis, GERD, Gastro Esophageal Reflux, Barrett Esophagus, Esophageal Cancer, Gastritis, Gastric Ulcer, Duodenal Ulcer, Intestinal Metaplasia, Gastric Cancer, Lymphocytic Colitis, Microscopic Colitis, Celiac Sprue, IBS, Irritable Bowel Syndrome, SIBO, NAFLD, Gallstone Disease
Interventions: Not listed
Lead sponsor: Viome; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Bothell, Washington

Conditions: Irritable Bowel Syndrome, Anxiety, Quality of Life
Interventions: Yoga; Behavioral
Lead sponsor: The Cooper Health System; Other
Eligibility: 12 Years to 21 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Camden, New Jersey

Conditions: Irritable Bowel Syndrome (IBS)
Interventions: ONO-2952, Placebo comparator; Drug
Lead sponsor: Ono Pharma USA Inc; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 4
States / cities: Boston, Massachusetts • St Louis, Missouri • Chapel Hill, North Carolina + 1 more

Search by objective public record fields.

Transdermal Administration by a Novel Wireless Iontophoresis Device

Assessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMA

Multi Modal Imaging: An MRI Study to Investigate Differences in the Structure and the Function of the Brain at Rest.

Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children

The Effect of Tegaserod on Patterns of Flow in the Small Bowel of Patients With Irritable Bowel Syndrome (IBS)

A Single Group Study to Evaluate the Effects of a Vaginal Probiotic on Vaginal and Digestive Health

Effects of Lubiprostone on Gastrointestinal Transit & pH in Irritable Bowel Syndrome (IBS) With Constipation

A Four Arm Study to Evaluate the Safety and Efficacy of 3 Different Doses of RVX-100 Versus Placebo in Subjects With Irritable Bowel Syndrome Accompanied by Diarrhea (IBS-D)

Psyllium in Pediatric IBS

Serine Proteases in Gastrointestinal Function and Irritable Bowel Syndrome (IBS)

Diet Reintroduction Study in Irritable Bowel Syndrome

Trans Auricular Vagal Nerve Stimulation in Patients With IBS-C

Vegetable Garden Feasibility Trial to Promote Function in Older Cancer Survivors

CRC Detection Reliable Assessment With Blood

A Study of 3 Doses of Dextofisopam in Females With Irritable Bowel Syndrome

Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea

Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome

Mindfulness vs. Support Groups for Irritable Bowel Syndrome

Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)

Effect of TU-100 on Rectal Compliance, Rectal Sensation and Small Bowel and Colonic Transit in Females With Constipation

Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome

Systems Biology of Gastrointestinal and Related Diseases

Standardized Yoga & Meditation Program for Stress Reduction for Adolescents With Irritable Bowel Syndrome

Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)